PRECISE and Temus agree five-year precision-health centre

Temus and Precision Health Research, Singapore (PRECISE) signed a memorandum of understanding to establish a five-year Joint Innovation Centre for Phase III of Singapore’s National Precision Medicine programme. The companies announced the agreement on 2 October; the signing took place at the Precision Health Partnerships in Singapore event.

Phase III, launched in November 2025, aims to sequence the genomes of about 450,000 residents and study how genomic information can be used responsibly in healthcare at population scale. The joint centre is intended to build the data and engineering foundations for that work.

PRECISE and Temus plan secure infrastructure to handle around 13.6 petabytes of genomic data, with capacity intended to grow beyond 60 petabytes. Their stated aims include shortening data processing from weeks to days and generating genome-wide association results for 100,000 genomes. These are planned capabilities, not results delivered by the new centre.

The work would cover data pipelines, research platforms and visualisation. Scientists and engineers are expected to develop shared systems for processing and analysing whole-genome data, with an operating model that keeps the platforms maintained as programme needs change. The partners also intend to establish safeguards for assessing new methods, including AI-enabled tools.

Temus plans to explore training pathways for specialist engineers and consultants in computational biology and bioinformatics, working alongside research and technology teams on live projects. The collaboration builds on work the two organisations have undertaken since 2024.

For Singapore’s precision-health programme, the development is a five-year commitment to shared infrastructure and specialist capacity.

Source: Temus’s 2 October 2026 PRECISE partnership announcement.